Schizophrenia: effects of aripiprazole in metabolic syndrome

Silva, Deborah Galvão Coelho da; Kanazawa, Luiz Kae Sales; Vecchia, Débora Dalla

doi:10.1590/s2175-97902019000217840

Cited by 4 publications

(9 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Quanto ao tipo de estudo, oito são estudos de cunho transversal, um corresponde a estudo prospectivo longitudinal e um a estudo metabolômico. Aponta-se, ainda, que houve uma prevalência de estudos (n= 9) de caráter internacional, observando-se uma maior concentração nos países Asiáticos (n= 4), sendo Os antipsicóticos são divididos em duas classes terapêuticas que diferem um do outro, basicamente, por potência terapêutica e afinidade em relação aos receptores, de modo que tais afinidades estão diretamente relacionadas com a eficácia clínica, resposta terapêutica, bem como para o desenvolvimento de efeitos adversos (SILVA et al, 2019).…”

Section: Resultsunclassified

“…Porém, o aumento do risco de dislipidemias, diabetes, doenças cardiovasculares e morte prematura são itens que necessitam de mais estudos que busquem compreender essa associação. (SILVA et al, 2019;OLMOS et al, 2017).…”

Section: Resultsunclassified

“…Autores Fármacos Psicotrópicos Seow et al, 2017;Alswalt et al, 2017Típicos (n=2) Jeon et al, 2017Paredes et al, 2014;Saloojee et al, 2014;Silva et al, 2019;Freitas et al, 2016;Santini et al, 2016;Olmos et al, 2017;Saloojee et al, 2016;Freitas et al, 2015;Sampaio et al, 2016. Atípicos (n=10) Sugawara et al, 2014 Não referido (n= 1)…”

Section: Quadro 4 Principais Antipsicóticos Utilizadosunclassified

“…Identificou-se em menor proporção (ALSWALT et al, 2017;SILVA et al, 2019;SALOOJEE et al, 2016) a utilização de distintos critérios para classificação da Síndrome Metabólica, sendo eles: International Diabetes Federation (IDF), the American Latin Association of Diabetes (ALAD), Joint…”

Section: Quadro 4 Principais Antipsicóticos Utilizadosunclassified

“…Observou-se que houve prevalência de associação significativa entre antipsicóticos atípicos e Síndrome Metabólica (JEON et al, 2017;SILVA et al, 2019;OLMOS et al, 2017;SANTINI et al, 2016;FREITAS et al, 2015). Por outro lado, em menor proporção, constataram-se alterações metabólicas por análise de fatores individuais em indivíduos expostos à antipsicóticos, não havendo, assim, utilização de critérios para classificação da Síndrome Metabólica (PAREDES et al, 2014;SALOOJEE et al, 2014;SALOOJEE et al, 2016;SAMPAIO et al, 2016).…”

Section: Quadro 4 Principais Antipsicóticos Utilizadosunclassified

See 4 more Smart Citations

Presença De Síndrome Metabólica Em Pacientes Expostos À Antipsicóticos: Uma Revisão Sistemática

Oliveira

Silva

Lima

et al. 2021

Edu., Ciência e Saúde

View full text Add to dashboard Cite

A administração de fármacos antipsicóticos representa uma intervenção amplamente utilizada na prática clínica como parte do tratamento de pessoas com transtorno psíquico. Contudo, a literatura tem associado o uso dessa classe de medicamentos a alterações metabólicas, caso não administrados de maneira correta. Objetivou-se avaliar a presença da Síndrome Metabólica (SM) e sua relação com a utilização de antipsicóticos. Revisão sistemática realizada de abril a maio de 2021, nas bases de dados: MedLine, LILACS, Portal de Periódicos CAPES e SCIELO, utilizando os seguintes descritores: Antipsicóticos, Síndrome Metabólica, Perfil Nutricional, junto aos critérios de inclusão e exclusão. Verificouse relação bem documentada do uso de antipsicóticos atípicos e alterações metabólicas em pacientes diagnosticados com esquizofrenia. Aponta-se como limitações dos estudos a dificuldade em identificar a Síndrome Metabólica devido à ausência de um padrão-ouro decorrente das distintas classificações existentes, bem como ausência de dados quanto ao consumo alimentar e estilo de vida dos pacientes, que permitiriam o estabelecimento de uma melhor associação entre os antipsicóticos e Síndrome Metabólica.

show abstract

Section: Resultsunclassified

Section: Quadro 4 Principais Antipsicóticos Utilizadosunclassified

See 3 more Smart Citations

Presença De Síndrome Metabólica Em Pacientes Expostos À Antipsicóticos: Uma Revisão Sistemática

Oliveira

Silva

Lima

et al. 2021

Edu., Ciência e Saúde

View full text Add to dashboard Cite

show abstract

The antimanic-like effects of andrographolide and quercetin

Kanazawa¹

View full text Add to dashboard Cite

People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.• The final author version and the galley proof are versions of the publication after peer review.• The final published version features the final layout of the paper including the volume, issue and page numbers. Link to publication General rightsCopyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal.If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

show abstract

Метаболический Профиль Пациентов С Шизофренией

Khaustova¹

2021

Психиатрия

View full text Add to dashboard Cite

Пациенты с шизофренией имеют повышенную предрасположенность к формированию нарушений соматического здоровья, обусловленную патогенетическим влиянием болезни на органы и системы организма человека. Дополнительными факторами, ухудшающими метаболический профиль пациентов с шизофренией, выступают выбор ими нездорового образа жизни, влияние антипсихотических препаратов или патологические изменения, предрасполагающие к метаболическим нарушениям.Метаболические нарушения часто возникают у пациентов, принимающих антипсихотические препараты, что вызывает растущее беспокойство у клиницистов. Определенные нейролептики в течение всего нескольких недель могут ухудшить метаболический профиль в уже восприимчивой когорте, поэтому метаболический мониторинг должен сопровождать назначение антипсихотиков. Мониторинг метаболических факторов риска, таких как повышенный уровень холестерина или глюкозы крови, и, при необходимости, их коррекция являются важными аспектами лечения, но мониторинг часто не обеспечивает оптимального лечения.Когда во время лечения антипсихотиками возникают серьезные метаболические нарушения, переход на препарат с хорошим профилем метаболической безопасности следует рассматривать как первый вариант терапии. Арипипразол значительно превосходит другие препараты, используемые для лечения шизофрении, показывая удовлетворительный клинический профиль с хорошей переносимостью и меньшей частотой побочных эффектов. Он может использоваться в качестве наиболее экономичного варианта монотерапии для улучшения и даже нормализации метаболического статуса пациентов, у которых развиваются метаболические нарушения. Добавление арипипразола к антипсихотической терапии также ведет к улучшению метаболических параметров и, таким образом, может быть использовано у тех пациентов, у которых переход на другой антипсихотик нежелателен по психиатрическим причинам, таким как наличие стойкого психоза.Современные клинические рекомендации предполагают использование монотерапии арипипразолом в качестве первой линии терапии у пациентов с неблагоприятным метаболическим профилем, а при наличии у пациента стойкого психоза – комбинировать его с клозапином, оланзапином, рисперидоном или галоперидолом для коррекции метаболического профиля. Patients with schizophrenia have an increased predisposition to the formation of somatic health disorders due to the pathogenetic effect of the disease on the organs and systems of the human body. Additional factors that worsen the metabolic profile of patients with schizophrenia are their choice of unhealthy lifestyles, the effect of antipsychotic drugs, or pathological changes that predispose to metabolic disorders.Metabolic abnormalities often occur in the patients who take antipsychotic drugs, which is a growing concern among clinicians. Some antipsychotics can worsen the metabolic profile in already susceptible cohort during only a few weeks. So, metabolic monitoring should accompany antipsychotics. Monitoring of metabolic risk factors such as elevated cholesterol or glucose levels and correcting them if necessary are important aspects of treatment, but monitoring often does not provide optimal treatment.When serious metabolic disorders occur during antipsychotic treatment, switching to a drug with a good metabolic safety profile should be considered as the first treatment option. Aripiprazole is significantly superior to other drugs used in the treatment of schizophrenia, showing a favourable clinical profile with good tolerance and fewer side effects. It can be used as the most economical monotherapy option to improve and even normalize the metabolic status of patients who develop metabolic disorders. Addition of aripiprazole to antipsychotic therapy also leads to improvement of metabolic parameters. This method can be used in those patients, in who switching to another antipsychotic is undesirable for psychiatric reasons, such as persistent psychosis.Current clinical guidelines suggest aripiprazole monotherapy as the first line in patients with unfavourable metabolic profile. If the patient has persistent psychosis, combine it with clozapine, olanzapine, risperidone, or haloperidol to correct the metabolic profile.

show abstract

Schizophrenia: effects of aripiprazole in metabolic syndrome

Cited by 4 publications

References 30 publications

Presença De Síndrome Metabólica Em Pacientes Expostos À Antipsicóticos: Uma Revisão Sistemática

Presença De Síndrome Metabólica Em Pacientes Expostos À Antipsicóticos: Uma Revisão Sistemática

The antimanic-like effects of andrographolide and quercetin

Метаболический Профиль Пациентов С Шизофренией

Contact Info

Product

Resources

About